Analysts Set PDS Biotechnology Co. (NASDAQ:PDSB) Price Target at $14.25

PDS Biotechnology Co. (NASDAQ:PDSB) has received an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.25.

Several research firms have weighed in on PDSB. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a report on Thursday, October 24th.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $3.29 on Friday. The firm has a market capitalization of $121.14 million, a price-to-earnings ratio of -2.70 and a beta of 1.93. The stock has a fifty day moving average of $3.25 and a 200 day moving average of $3.28. PDS Biotechnology has a 52 week low of $2.53 and a 52 week high of $6.85. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. As a group, research analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Inspirion Wealth Advisors LLC increased its holdings in shares of PDS Biotechnology by 1.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after purchasing an additional 4,917 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology during the second quarter valued at approximately $55,000. Ground Swell Capital LLC bought a new position in PDS Biotechnology in the second quarter worth approximately $67,000. Vontobel Holding Ltd. boosted its stake in shares of PDS Biotechnology by 233.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after acquiring an additional 28,000 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $115,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.